Monitor for future developments such as patent grants, clinical trial progress, or partnerships that could validate the commercial potential of these compounds.
Price Chart
Executive Summary
Clearmind Medicine Inc. filed a patent application in India for next-generation psychedelic-based compounds aimed at treating mental health disorders and addiction. This expands its global intellectual property portfolio, building on its licensing agreement with Yissum Research Development Company. The filing is a routine IP development with no immediate financial impact.
Key Facts
- Clearmind Medicine filed a patent application in India for novel psychedelic-based compounds targeting mental health and addiction.
- The patent application is part of an expanding global IP portfolio that includes 19 patent families and 31 granted patents.
- The compounds are designed to be non-hallucinogenic and overcome limitations of classical psychedelics.
- No financial terms, revenue implications, or clinical trial results were disclosed.
Financial Impact
No quantifiable financial impact at this stage; patent filing is an early-stage R&D activity.
Risk Factors
- Patent may not be granted or could be issued in a limited form.
- High uncertainty in drug development; compounds may fail in clinical trials.
- Company operates in a speculative biotech segment with no near-term revenue visibility.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-035150 |
| Document: ea0283772-6k_clearmind.htm | 0001213900-26-035150 |
| Document: 0001213900-26-035150-index-headers.html | 0001213900-26-035150 |
| Document: 0001213900-26-035150-index.html | 0001213900-26-035150 |
| Document: 0001213900-26-035150.txt | 0001213900-26-035150 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $5.92 | awaiting T+60 | — | $5.95 (+0.47%) |
Oct 27, 2026 today | Press Release | $6.50 | awaiting T+60 | — | $5.95 (−8.50%) |
Oct 16, 2026 10d ago | 6-K | $6.00 | awaiting T+60 | — | $5.95 (+0.87%) |
Oct 13, 2026 14d ago | 6-K | $6.23 | awaiting T+60 | — | $5.95 (−4.53%) |
Oct 8, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $5.95 (−9.88%) |
Oct 7, 2026 20d ago | 6-K | $6.60 | awaiting T+60 | — | $5.95 (−9.88%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $5.95 (+599.72%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $5.95 (+599.72%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $5.95 (−13.35%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $5.95 (+530.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers